Polaryx Therapeutics' chief medical officer resigns effective immediately
Lisa Bollinger's departure was disclosed in a July 21, 2026 filing, with the company saying it does not expect the move to disrupt existing plans.
Polaryx Therapeutics, Inc. disclosed in a Form 8-K that Lisa Bollinger, MD, Chief Medical Officer of the company, resigned from her position effective immediately on July 19, 2026.1
The company said it does not expect Dr. Bollinger's departure to change the clinical timelines, regulatory plans, or development strategy it has already disclosed.1
Polaryx stated that it has begun looking for a replacement for the role.1 In the meantime, the company said the duties Dr. Bollinger held will be split among current members of its leadership team.1
The filing was signed by Alex Yang, Chief Executive Officer, and dated July 21, 2026. Polaryx Therapeutics trades on The Nasdaq Capital Market under the ticker PLYX, and the company is incorporated in Nevada with executive offices in Paramus, New Jersey.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.